This guidance will fully update the following:
Following on from information provided to NICE by the company in June 2017, the appraisal of Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 965 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
| External Assessment Group | tbc |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Following on from information provided to NICE by the company in June 2017, the appraisal of Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 23 June 2017 | Suspended. Now ID1101 |
| 29 February 2016 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual